« Back
Evaluation of an automated SPE method for samples derived from capillary microsampling
Evaluation of an automated SPE method for samples derived from capillary microsampling
Submitted on 21 Nov 2013

Paul-Gerhard Lassahn1, Petra Lombardi1, Winfried Wagner-Redeker1, Marie-Claude Robaudi-Fraschini2, Reto Bolliger3, Guenter Boehm3
1 Swiss BioAnalytics AG, Basel, Switzerland; 2 Debiopharm International S.A., Lausanne, Switzerland; 3 CTC Analytics AG, Zwingen, Switzerland
This poster was presented at EBF 2013, Barcelona
Poster Views: 1,671
View poster »   Find out more »
Poster Abstract
• The automated workflow described gave equivalent results (LLOQ, precision, accuracy) compared to samples processed manually by protein precipitation. The overall time/sample is slightly higher for the automated protocol. However, since only minimal intervention is required, process safety is superior and human resources are freed up for other tasks.

• The automated protocol may be further optimized in several aspects. As shown a volume of 20 μL is sufficient for complete elution of the analyte from the cartridge. Figure 6 indicates that a loading volume of 2-5 μL diluted plasma is sufficient allowing the use of low-volume samples. Both aspects are important for further optimizing this protocol for analysis of samples originating from studies using microsampling techniques.

• Methods for the automated optimization of the SPE conditions exist and will be applied in future studies.

Nilsson LB, Ahnoff M, Jonsson O; Bioanalysis (2013) 5(6), 731–738Report abuse »
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters

Clinical Trial Summaries: Readability to Effectively Inform Patients
Autumn Sky Watson

Comparison of hepatocytes in monolayer and RAFT™ 3D Cell Culture System
Therese Willstaedt, Maureen Bunger, Lubna Hussain, and Theresa D’Souza

Salamanca Grosso, G.; Osorio Tangafarife, M.P.

The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2

Validation of Factor IIa Assay for Dalteparin Sodium
Dr Amitabha De, Kiran Shah, Prajakta Ambre, Jyoti Gupta